---
sidebar_position: 78
---

# æ–‡ç» 78ï¼šA multi-view validation framework for LLM-generated knowledge graphs of chronic kidney disease

**English Title**: A multi-view validation framework for LLM-generated knowledge graphs of chronic kidney disease

**ä¸­æ–‡æ¨™é¡Œ**: æ…¢æ€§è…è‡Ÿç—… LLM ç”ŸæˆçŸ¥è­˜åœ–è­œçš„å¤šè¦–è§’é©—è­‰æ¡†æ¶
**PMID**: 40810826
**æœŸåˆŠ**: æœªçŸ¥æœŸåˆŠ
**è©•åˆ†**: ä¸­ç­‰
**æ‡‰ç”¨é ˜åŸŸ**: 8
**DOI**: https://doi.org/10.1007/s11548-025-03495-x

---

## ğŸ“Œ ç¬¬ä¸€å¼µï¼šæ ¸å¿ƒè§€é»å¡

### ä¸»è¦ç™¼ç¾
ä¸­ç­‰

### æ–‡ç»æ‘˜è¦ï¼ˆAbstractï¼‰
PURPOSE: The goal of our work is to develop a multi-view validation framework for evaluating LLM-generated knowledge graph (KG) triples. The proposed approach aims to address the lack of established validation procedure in the context of LLM-supported KG construction. METHODS: The proposed framework evaluates the LLM-generated triples across three dimensions: semantic plausibility, ontology-grounded type compatibility, and structural importance. We demonstrate the performance for GPT-4 generated concept-specific (e.g., for medications, diagnosis, procedures) triples in the context of chronic kidney disease (CKD). RESULTS: The proposed approach consistently achieves high-quality results across evaluated GPT-4 generated triples, strong semantic plausibility (semantic score mean: 0.79), excellent type compatibility (type score mean: 0.84), and high structural importance of entities within the CKD knowledge domain (ResourceRank mean: 0.94). CONCLUSION: The validation framework offers a reliable and scalable method for evaluating quality and validity of LLM-generated triples across three views: semantic plausibility, type compatibility, and structural importance. The framework demonstrates robust performance in filtering high-quality triples and lays a strong foundation for fast and reliable medical KG construction and validation.

### é—œéµæ•¸æ“š
- **ç ”ç©¶é¡å‹**: æœªåˆ†é¡
- **åœ‹å®¶/åœ°å€**: å¾…æŸ¥
- **ç™¼è¡¨å¹´ä»½**: å¾…æŸ¥
- **ROI æ•¸å€¼**: ç„¡æ•¸å€¼

### æ ¸å¿ƒå‰µæ–°é»
æœ¬ç ”ç©¶çš„ä¸»è¦å‰µæ–°åœ¨æ–¼ï¼šä¸­ç­‰

---

## âœï¸ ç¬¬äºŒå¼µï¼šParaphrase å¡

### ç ”ç©¶ç›®çš„èˆ‡æ–¹æ³•
æœ¬ç ”ç©¶èšç„¦æ–¼8é ˜åŸŸï¼Œæ—¨åœ¨æ¢è¨ AI æŠ€è¡“åœ¨é†«ç™‚å ´æ™¯ä¸­çš„æ‡‰ç”¨ã€‚

### ä¸»è¦è²¢ç»
ç ”ç©¶æå‡ºäº†ä¸­ç­‰ï¼Œç‚ºè‡¨åºŠå¯¦è¸æä¾›äº†æ–°çš„è§£æ±ºæ–¹æ¡ˆã€‚

### æŠ€è¡“ç‰¹é»
- æ‡‰ç”¨å ´æ™¯ï¼š8
- å‰µæ–°ç¨‹åº¦ï¼šè©•åˆ† ä¸­ç­‰/10
- æœŸåˆŠå½±éŸ¿ï¼šç™¼è¡¨æ–¼ æœªçŸ¥æœŸåˆŠ

---

## â“ ç¬¬ä¸‰å¼µï¼šå•ç­”å¡

### Q1: é€™é …ç ”ç©¶è§£æ±ºäº†ä»€éº¼å•é¡Œï¼Ÿ
A: æœ¬ç ”ç©¶é‡å°8é ˜åŸŸçš„æŒ‘æˆ°ï¼Œæå‡ºäº†åŸºæ–¼ AI çš„è§£æ±ºæ–¹æ¡ˆã€‚

### Q2: æ¡ç”¨äº†ä»€éº¼æŠ€è¡“æ–¹æ³•ï¼Ÿ
A: ä¸­ç­‰

### Q3: ç ”ç©¶çš„ä¸»è¦æˆæœæ˜¯ä»€éº¼ï¼Ÿ
A: ç ”ç©¶ç²å¾—äº† ä¸­ç­‰ åˆ†çš„å°ˆå®¶è©•åˆ†ï¼Œè­‰æ˜äº†å…¶åœ¨8é ˜åŸŸçš„æ‡‰ç”¨åƒ¹å€¼ã€‚

### Q4: æœ‰å“ªäº›å¯¦éš›æ‡‰ç”¨å ´æ™¯ï¼Ÿ
A: ä¸»è¦æ‡‰ç”¨æ–¼8ï¼Œå¯ç”¨æ–¼æ”¹å–„é†«ç™‚æœå‹™å“è³ªå’Œæ•ˆç‡ã€‚

---

## ğŸ¤” ç¬¬å››å¼µï¼šä¾‹å¤–å¡

### æ½›åœ¨é™åˆ¶
1. **ç ”ç©¶ç¯„åœ**: ç ”ç©¶è©•åˆ†ç‚º ä¸­ç­‰/10ï¼Œå¯èƒ½å­˜åœ¨æ”¹é€²ç©ºé–“
2. **åœ°å€å·®ç•°**: ç ”ç©¶ä¾†è‡ªå¾…æŸ¥ï¼Œå…¶ä»–åœ°å€é©ç”¨æ€§éœ€é©—è­‰
3. **ROI æ•¸æ“š**: ç„¡æ•¸å€¼ï¼Œç¶“æ¿Ÿæ•ˆç›Šè©•ä¼°å¯èƒ½ä¸å®Œæ•´

### éœ€è¦é€²ä¸€æ­¥æ¢è¨çš„å•é¡Œ
1. è©²æŠ€è¡“åœ¨ä¸åŒè¦æ¨¡é†«é™¢çš„é©ç”¨æ€§å¦‚ä½•ï¼Ÿ
2. é•·æœŸä½¿ç”¨çš„æ•ˆæœå’Œç©©å®šæ€§æ˜¯å¦ç¶“éé©—è­‰ï¼Ÿ
3. èˆ‡ç¾æœ‰ç³»çµ±æ•´åˆæ™‚å¯èƒ½é¢è‡¨å“ªäº›æŒ‘æˆ°ï¼Ÿ

### æ‰¹åˆ¤æ€§æ€è€ƒ
- **æŠ€è¡“æˆç†Ÿåº¦**: éœ€è¦è©•ä¼°å¾ç ”ç©¶åˆ°å¯¦éš›éƒ¨ç½²çš„è·é›¢
- **æˆæœ¬æ•ˆç›Š**: ç„¡æ•¸å€¼ï¼Œéœ€è¦æ›´è©³ç´°çš„ç¶“æ¿Ÿåˆ†æ
- **å€«ç†è€ƒé‡**: AI åœ¨8æ‡‰ç”¨æ™‚çš„å€«ç†å’Œéš±ç§å•é¡Œ
- **å¯æ¨å»£æ€§**: ç ”ç©¶çµæœåœ¨å…¶ä»–é†«ç™‚å ´æ™¯çš„é©ç”¨æ€§

---

## ğŸ“š åƒè€ƒè³‡è¨Š
- **PMID**: [40810826](https://pubmed.ncbi.nlm.nih.gov/40810826/)
- **DOI**: https://doi.org/10.1007/s11548-025-03495-x
- **æœŸåˆŠ**: æœªçŸ¥æœŸåˆŠ
